MIRA news

MIRA Pharmaceuticals posted positive preclinical results for its pain drug candidate MIRA-55, demonstrating the potential to rival popular drugs like Celebrex for chronic inflammatory pain without observed tolerance.

MIRA Pharmaceuticals submitted the Phase 2a protocol for Ketamir-2 to IRB after FDA review, targeting site initiation in Q1 2027 to evaluate efficacy in chemotherapy-induced peripheral neuropathy.

MIRA Pharmaceuticals announced successful formulation results for MIRA-55, achieving favorable bioavailability and distribution to target tissues. This milestone supports the validation of the non-opioid candidate's potential as a differentiated pain therapy.

MIRA Pharmaceuticals reported successful preclinical data for obesity drug candidate SKNY-1, demonstrating favorable oral bioavailability and brain penetration. These findings strengthen the development profile of a potential once-daily oral therapy for both obesity and addiction.

Mira Pharmaceuticals announced submission of a Phase 2a clinical trial protocol for Ketamir-2, an oral NMDA receptor modulator, to treat chemotherapy-induced peripheral neuropathy (CIPN), which affects millions of cancer patients annually with no approved therapies. The randomized, double-blind, pla…

MIRA Pharmaceuticals entered into a consulting agreement with Andriy Mushak to serve as fractional chief financial officer effective June 6, 2026, providing senior financial leadership for SEC reporting, audit readiness, and capital-markets support. The engagement strengthens the company's financial…

Mira Pharmaceuticals submitted an exhibit filing with the SEC containing contract documentation. The specific terms and business impact require access to the complete exhibit content.

Mira Pharmaceuticals submitted an exhibit filing (EX-10.1) with the SEC. The specific content and market impact cannot be determined from the limited document header provided.